↓ Skip to main content

The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study

Overview of attention for article published in BMC Cancer, April 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 7,204)
  • High Attention Score compared to outputs of the same age (98th percentile)

Mentioned by

news
9 news outlets
blogs
2 blogs
twitter
125 tweeters
patent
1 patent
facebook
2 Facebook pages
video
2 video uploaders

Readers on

mendeley
265 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study
Published in
BMC Cancer, April 2018
DOI 10.1186/s12885-018-4353-2
Pubmed ID
Authors

Stephan P. Bauersfeld, Christian S. Kessler, Manfred Wischnewsky, Annette Jaensch, Nico Steckhan, Rainer Stange, Barbara Kunz, Barbara Brückner, Jalid Sehouli, Andreas Michalsen

Abstract

This pilot trial aimed to study the feasibility and effects on quality of life (QOL) and well-being of short-term fasting (STF) during chemotherapy in patients with gynecological cancer. In an individually-randomized cross-over trial patients with gynecological cancer, 4 to 6 planned chemotherapy cycles were included. Thirty-four patients were randomized to STF in the first half of chemotherapies followed by normocaloric diet (group A;n = 18) or vice versa (group B;n = 16). Fasting started 36 h before and ended 24 h after chemotherapy (60 h-fasting period). QOL was assessed by the FACIT-measurement system. The chemotherapy-induced reduction of QOL was less than the Minimally Important Difference (MID; FACT-G = 5) with STF but greater than the MID for non-fasted periods. The mean chemotherapy-induced deterioration of total FACIT-F was 10.4 ± 5.3 for fasted and 27.0 ± 6.3 for non-fasted cycles in group A and 14.1 ± 5.6 for non-fasted and 11.0 ± 5.6 for fasted cycles in group B. There were no serious adverse effects. STF during chemotherapy is well tolerated and appears to improve QOL and fatigue during chemotherapy. Larger studies should prove the effect of STF as an adjunct to chemotherapy. This trial was registered at clinicaltrials.gov: NCT01954836 .

Twitter Demographics

The data shown below were collected from the profiles of 125 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 265 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 265 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 46 17%
Student > Master 39 15%
Researcher 20 8%
Student > Ph. D. Student 17 6%
Student > Doctoral Student 16 6%
Other 46 17%
Unknown 81 31%
Readers by discipline Count As %
Medicine and Dentistry 56 21%
Nursing and Health Professions 48 18%
Biochemistry, Genetics and Molecular Biology 27 10%
Agricultural and Biological Sciences 14 5%
Psychology 6 2%
Other 22 8%
Unknown 92 35%

Attention Score in Context

This research output has an Altmetric Attention Score of 168. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 January 2022.
All research outputs
#160,797
of 20,117,040 outputs
Outputs from BMC Cancer
#9
of 7,204 outputs
Outputs of similar age
#4,633
of 294,058 outputs
Outputs of similar age from BMC Cancer
#1
of 1 outputs
Altmetric has tracked 20,117,040 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,204 research outputs from this source. They receive a mean Attention Score of 4.1. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 294,058 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them